Tag:
Cell Genesys
Latest Headlines
Latest Headlines
SPOTLIGHT: Cell Genesys reports vaccine data
Cell Genesys reports vaccine dataCell Genesys today reported encouraging clinical data from a Phase II trial of GVAX vaccine for chronic myelogenous leukemia.
ALSO NOTED: German court rules against Pfizer; Diamyd buys Nurel; Genzyme acquires San Diego plant; and much more...
> A German court has ruled that regulators' price caps on Pfizer's Lipitor are legal. Pfizer's sales in Germany have plunged by one-fifth in the first half of this year. Report > Sweden's Diamyd Medical has agreed to acquire all of the outstanding shares in Nurel, a Pittsburgh-based biotech valued at $1.5 million. …
ALSO NOTED: UK officials give limited OK to Sativex; Lipitor fails to beat Zocor in head-to-head trial; Celsion to focus on dru
> Shares of the UK's GW Pharmaceuticals surged after UK officials indicated that its cannabis-based painkiller could be imported from Canada for certain uses. Earlier this year British regulators said they needed more data from GW before they could make a final decision on Sativex. Report > A head-to-head trial of Pfizer's Lipitor versus Zocor failed to demonstrate that Lipitor was any better …
Cell Genesys cuts jobs, focuses on lead drugs
Citing a strategic realignment, Cell Genesys has decided to slash 95 jobs -- one quarter of its work force -- as it scales back some of its operations and concentrates on its leading drug candidates. The biotech touted positive data last month on GVAX for prostate cancer, pancreatic cancer and leukemia. It also wants to push CG0070 for recurrent bladder cancer. Cell Genesys is putting its San Diego manufacturing site up for sale and will reduce its operations in Memphis. The …
- « first
- ‹ previous
- 1
- 2
- 3
